The American Diabetes Association (ADA) advises against using compounded versions of glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA medications, due to safety concerns and potential dosing errors. They recommend using only FDA-approved versions of these medications for treating type 2 diabetes, reducing cardiovascular and kidney disease risk, and managing weight. The ADA statement notes that counterfeit and unregulated versions of these medications pose risks to individuals’ safety. Switching to an alternative FDA-approved medication is recommended if a certain medication is unavailable. The ADA advises individuals and healthcare providers to discuss product use, verify dosing guidance, and report any adverse events to the FDA.
Source link
ADA Advises Against Using Compounded GLP-1 RA Medications
